[144] Royalty Pharma plc SEC Filing

Royalty Pharma plc reported a proposed sale under Form 144 for 13,684 shares.

Rhea-AI Filing Summary

Royalty Pharma plc reported a proposed sale under Form 144 for 13,684 shares. The filing lists related equity performance awards granted on 08/06/2025 (2,772 shares), 11/05/2025 (4,626 shares) and 02/11/2026 (6,286 shares).

The cover shows an aggregate value of $726,137.82 and the filing is dated 05/14/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 05:22 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001838139
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Royalty Pharma plc
SEC File Number	001-39329
Address of Issuer	110 EAST 59TH STREET NEW YORK NEW YORK 10022
Phone	(212) 883-0200
Name of Person for Whose Account the Securities are To Be Sold	Urist Marshall
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	13684	726137.82	443274104	05/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	08/06/2025	Equity Performance Award	Royalty Pharma plc			2772	08/06/2025	Granted as part of issuer equity compensation program
Class A Ordinary Shares	11/05/2025	Equity Performance Award	Royalty Pharma plc			4626	11/05/2025	Granted as part of issuer equity compensation program
Class A Ordinary Shares	02/11/2026	Equity Performance Award	Royalty Pharma plc			6286	02/11/2026	Granted as part of issuer equity compensation program

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	05/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Marshall Urist
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)